Part 2: Clinical presentation and treatment (see part 1 here) Introduction IgG4-related disease (IgG4-RD) is understood to have a vast clinicopathological spectrum; nearly every organ has had reported involvement. Similarly, IgG4-related ophthalmic disease (IgG4-ROD) is known to affect nearly every...
More than half of drivers who are dazzled by headlights – 57% – say the problem has worsened over the last 12 months with only three-in-10 (31) disagreeing, found comprehensive new RAC research supported by The College of Optometrists [1]....
Glaucoma UK is delighted to announce the winners of its 2026 Excellence in Glaucoma Care Awards, recognising outstanding individuals and teams who are transforming glaucoma care for patients across the UK. Individual Excellence in Glaucoma Care Award (joint winners) Mr...
Age-related macular degeneration (AMD) is a neurodegenerative complex disease of the eye and a major cause of blindness and visual impairment among the elderly worldwide. The early stages of the disease are characterised by asymptomatic pigmentary abnormalities and accumulation of...
1 April 2017
| Sancy Low, Paul J Foster (Prof)
|
EYE - Glaucoma
Angle closure glaucoma (ACG) is not widely known to be a familial condition, yet the recent explosion of genetic data and large scale genome wide investigations have confirmed at least 13 genetic loci associated with ACG [1], and provided some...
Treatment practice in the management of neovascular age-related macular degeneration (AMD) and diabetic macular oedema (DMO) illustrate increasing adoption of patient-tailored treatment approaches based on initial diagnosis and regular monitoring of imaging and visual outcomes in routine clinical care. The...
Age-related macular degeneration (AMD) is a multifactorial condition influenced by genetics and lifestyle factors (Table 1). This article outlines several recent advances in AMD genetics, as well as evolving therapeutic concepts and established practical measures for the treatment and /...
Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...
The goal of glaucoma management is to prevent visual loss and disease progression in the patient’s lifetime through effective lowering of intraocular pressure (IOP), the primary modifiable risk factor in glaucoma. Sustained and consistent IOP reduction is key to halting...
Trying to spot the trends at this year’s SILMO in Paris, one of the largest optical fairs in the world, was a tough ask. Thin metals, especially in rose gold, abounded, but that’s now; tomorrow remained elusive.